{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:25:20Z","timestamp":1792113920471,"version":"4.4.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.bioorg.2022.106038","type":"journal-article","created":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T20:08:26Z","timestamp":1658002106000},"page":"106038","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["New benzimidazole based hybrids: Synthesis, molecular modeling study and anticancer evaluation as TopoII inhibitors"],"prefix":"10.1016","volume":"127","author":[{"given":"Nareman A.","family":"Nawareg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amany S.","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5976-0130","authenticated-orcid":false,"given":"Shahenda M.","family":"El-Messery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magda N.A.","family":"Nasr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bioorg.2022.106038_b0005","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2022.106038_b0010","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.ejmech.2018.06.061","article-title":"Design, synthesis, antiproliferative activity, molecular docking and cell cycle analysis of some novel (morpholinosulfonyl) isatins with potential EGFR inhibitory activity","volume":"156","author":"Ammar","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2022.106038_b0015","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202100580","article-title":"Design, Synthesis, Cytotoxic Screening and Molecular Docking Studies of Novel Hybrid Thiosemicarbazone Derivatives as Anticancer Agents","volume":"18","author":"Mohammed","year":"2021","journal-title":"Chem. Biodivers."},{"issue":"5","key":"10.1016\/j.bioorg.2022.106038_b0020","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrc2607","article-title":"Targeting DNA topoisomerase II in cancer chemotherapy","volume":"9","author":"Nitiss","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.bioorg.2022.106038_b0025","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3109\/14756366.2012.658785","article-title":"Topoisomerase as target for antibacterial and anticancer drug discovery","volume":"28","author":"Kathiravan","year":"2013","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2022.106038_b0030","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1021\/acs.jmedchem.5b01284","article-title":"Synthesis and mechanism studies of 1, 3-benzoazolyl substituted pyrrolo [2, 3-b] pyrazine derivatives as nonintercalative topoisomerase II catalytic inhibitors","volume":"59","author":"Li","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106038_b0035","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.633142","article-title":"Discovery of New Catalytic Topoisomerase II Inhibitors for Anticancer Therapeutics","volume":"10","author":"Matias-Barrios","year":"2021","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.bioorg.2022.106038_b0040","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.201700040","article-title":"Benzimidazole scaffold as anticancer agent: synthetic approaches and structure\u2013activity relationship","volume":"350","author":"Shrivastava","year":"2017","journal-title":"Archiv der Pharmazie"},{"issue":"45","key":"10.1016\/j.bioorg.2022.106038_b0045","doi-asserted-by":"crossref","first-page":"28313","DOI":"10.1039\/C6RA24662A","article-title":"Small hybrid heteroaromatics: resourceful biological tools in cancer research","volume":"7","author":"Abbot","year":"2017","journal-title":"RSC Adv."},{"issue":"3","key":"10.1016\/j.bioorg.2022.106038_b0050","first-page":"884","article-title":"Dual inhibitors of human DNA topoisomerase II and other cancer-related targets","volume":"63","author":"Zi","year":"2019","journal-title":"J. Med. Chem."},{"issue":"14","key":"10.1016\/j.bioorg.2022.106038_b0055","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.3390\/molecules25143180","article-title":"Design, Synthesis and Anti-Tumor Activity of Novel Benzimidazole-Chalcone Hybrids as Non-Intercalative Topoisomerase II Catalytic Inhibitors","volume":"25","author":"Zhou","year":"2020","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.bioorg.2022.106038_b0060","first-page":"1","article-title":"Versatile mechanisms of 2-substituted benzimidazoles in targeted cancer therapy","volume":"6","author":"Ibrahim","year":"2020","journal-title":"Future J. Pharm. Sci."},{"issue":"7","key":"10.1016\/j.bioorg.2022.106038_b0065","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1039\/C8MD00278A","article-title":"Design, synthesis and biological evaluation of benzimidazole\u2013rhodanine conjugates as potent topoisomerase II inhibitors","volume":"9","author":"Li","year":"2018","journal-title":"MedChemComm."},{"issue":"2","key":"10.1016\/j.bioorg.2022.106038_b0070","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.bbrc.2004.03.093","article-title":"Some fused heterocyclic compounds as eukaryotic topoisomerase II inhibitors","volume":"317","author":"Pinar","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bioorg.2022.106038_b0075","doi-asserted-by":"crossref","unstructured":"S.-O. Kim, K. Sakchaisri, T. NR, N.K. Soung, J.-H. Jang, Y.S. Kim, et al., STK295900, a dual inhibitor of topoisomerase 1 and 2, induces G2 arrest in the absence of DNA damage, PloS One 2013;8(1):e53908.","DOI":"10.1371\/journal.pone.0053908"},{"issue":"1","key":"10.1016\/j.bioorg.2022.106038_b0080","article-title":"Synthesis, evaluation, and in silico studies of 2-mercapto-5-substituted styryl-1, 3, 4-oxadiazoles as potential cytotoxic agents","volume":"44","author":"Vinjavarapu","year":"2020","journal-title":"Thai. J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.bioorg.2022.106038_b0085","first-page":"465","article-title":"Recent developments on 1, 2, 4-triazole nucleus in anticancer compounds: a review","volume":"16","author":"Kaur","year":"2016","journal-title":"Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents)"},{"issue":"4","key":"10.1016\/j.bioorg.2022.106038_b0090","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.3390\/app11041877","article-title":"Schiff Bases: Interesting Scaffolds with Promising Antitumoral Properties","volume":"11","author":"Iacopetta","year":"2021","journal-title":"Appl. Sci."},{"key":"10.1016\/j.bioorg.2022.106038_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115976","article-title":"Synthesis, anticancer and antimicrobial evaluation of new benzofuran based derivatives: PI3K inhibition, quorum sensing and molecular modeling study","volume":"31","author":"El-Khouly","year":"2021","journal-title":"Bioorg. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2022.106038_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115495","article-title":"Synthesis, state-of-the-art NMR-binding and molecular modeling study of new benzimidazole core derivatives as Pin1 inhibitors: Targeting breast cancer","volume":"28","author":"Nashaat","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106038_b0105","doi-asserted-by":"crossref","unstructured":"W.A. Ewes, M.A. Elmorsy, S.M. El-Messery, M.N. Nasr, Synthesis, biological evaluation and molecular modeling study of [1, 2, 4]-Triazolo [4, 3-c] quinazolines: New class of EGFR-TK inhibitors, Bioorg. Med. Chem. 2020;28(7):115373.","DOI":"10.1016\/j.bmc.2020.115373"},{"key":"10.1016\/j.bioorg.2022.106038_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103332","article-title":"Towards breast cancer targeting: Synthesis of tetrahydroindolocarbazoles, antibreast cancer evaluation, uPA inhibition, molecular genetic and molecular modeling studies","volume":"93","author":"Ahmed","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2022.106038_b0115","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.bioorg.2018.06.033","article-title":"Tetrahydroindolocarbazoles (THICZs) as new class of urokinase (uPA) inhibitors: Synthesis, anticancer evaluation, DNA-damage determination, and molecular modeling study","volume":"80","author":"El-Sharief","year":"2018","journal-title":"Bioorg. Chem."},{"issue":"22","key":"10.1016\/j.bioorg.2022.106038_b0120","doi-asserted-by":"crossref","first-page":"8692","DOI":"10.3390\/ijms21228692","article-title":"Groundbreaking anticancer activity of highly diversified oxadiazole scaffolds","volume":"21","author":"Benassi","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2022.106038_b0125","doi-asserted-by":"crossref","first-page":"S503","DOI":"10.1016\/j.arabjc.2012.10.010","article-title":"Synthesis, characterization and antimicrobial activity of 1, 3, 4-oxadiazole bearing 1H-benzimidazole derivatives","volume":"10","author":"Salahuddin","year":"2017","journal-title":"Arabian J. Chem."},{"key":"10.1016\/j.bioorg.2022.106038_b0130","doi-asserted-by":"crossref","first-page":"S342","DOI":"10.1016\/j.arabjc.2011.04.013","article-title":"Synthesis, characterization and pharmacological screening of novel benzimidazole derivatives","volume":"9","author":"Shaharyar","year":"2016","journal-title":"Arabian J. Chem."},{"key":"10.1016\/j.bioorg.2022.106038_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103076","article-title":"Dihydrofolate reductase inhibition effect of 5-substituted pyrido [2, 3-d] pyrimidines: Synthesis, antitumor activity and molecular modeling study","volume":"90","author":"Abdelaziz","year":"2019","journal-title":"Bioorg. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2022.106038_b0140","first-page":"93","article-title":"Novel pyrazolyl pyridazine derivatives likely to possess anti-inflammatory activity","volume":"2","author":"Yassin","year":"2010","journal-title":"J. Microbiol. Antimicrobials"},{"key":"10.1016\/j.bioorg.2022.106038_b0145","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejmech.2018.06.004","article-title":"Design, synthesis, molecular modeling and anti-proliferative evaluation of novel quinoxaline derivatives as potential DNA intercalators and topoisomerase II inhibitors","volume":"155","author":"Ibrahim","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106038_b0150","doi-asserted-by":"crossref","unstructured":"J. Silke, P. Meier, Inhibitor of apoptosis (IAP) proteins\u2013modulators of cell death and inflammation, Cold Spring Harbor Perspectives in Biology 2013;5(2):a008730.","DOI":"10.1101\/cshperspect.a008730"},{"issue":"12","key":"10.1016\/j.bioorg.2022.106038_b0155","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1016\/j.bbamcr.2016.09.012","article-title":"Activation of apoptosis signalling pathways by reactive oxygen species","volume":"1863","author":"Redza-Dutordoir","year":"2016","journal-title":"Biochim. Biophys. Acta (BBA)-Mol. Cell Res."},{"issue":"8","key":"10.1016\/j.bioorg.2022.106038_b0160","doi-asserted-by":"crossref","first-page":"12831","DOI":"10.18632\/oncotarget.14606","article-title":"A novel benzimidazole derivative, MBIC inhibits tumor growth and promotes apoptosis via activation of ROS-dependent JNK signaling pathway in hepatocellular carcinoma","volume":"8","author":"Dai","year":"2017","journal-title":"Oncotarget."},{"issue":"9","key":"10.1016\/j.bioorg.2022.106038_b0165","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/s41388-020-01587-3","article-title":"Transcription factors in colorectal cancer: molecular mechanism and therapeutic implications","volume":"40","author":"Xu","year":"2021","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.bioorg.2022.106038_b0170","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41568-019-0196-7","article-title":"Targeting transcription factors in cancer\u2014from undruggable to reality","volume":"19","author":"Bushweller","year":"2019","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.bioorg.2022.106038_b0175","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2174\/092986713804999402","article-title":"Recent advances in the development of catalytic inhibitors of human DNA topoisomerase II\u03b1 as novel anticancer agents","volume":"20","author":"Pogorelcnik","year":"2013","journal-title":"Curr. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2022.106038_b0180","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.xphs.2016.12.002","article-title":"Optimizing oral bioavailability in drug discovery: an overview of design and testing strategies and formulation options","volume":"106","author":"Aungst","year":"2017","journal-title":"J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.bioorg.2022.106038_b0185","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1021\/ci6003515","article-title":"ADME evaluation in drug discovery. 6. Can oral bioavailability in humans be effectively predicted by simple molecular property-based rules?","volume":"47","author":"Hou","year":"2007","journal-title":"J. Chem. Inf. Model."},{"issue":"1\u20133","key":"10.1016\/j.bioorg.2022.106038_b0190","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"23","author":"Lipinski","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.bioorg.2022.106038_b0195","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0022-1759(86)90368-6","article-title":"Rapid colorimetric assay for cell growth and survival: modifications to the tetrazolium dye procedure giving improved sensitivity and reliability","volume":"89","author":"Denizot","year":"1986","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.bioorg.2022.106038_b0200","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ejmech.2018.07.004","article-title":"Synthesis and anticancer activity of new dihydropyrimidinone derivatives","volume":"156","author":"Mostafa","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"14","key":"10.1016\/j.bioorg.2022.106038_b0205","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1021\/jm200235u","article-title":"N-fused imidazoles as novel anticancer agents that inhibit catalytic activity of topoisomerase II\u03b1 and induce apoptosis in G1\/S phase","volume":"54","author":"Baviskar","year":"2011","journal-title":"J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206822004448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206822004448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:44:58Z","timestamp":1758617098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206822004448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":41,"alternative-id":["S0045206822004448"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2022.106038","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New benzimidazole based hybrids: Synthesis, molecular modeling study and anticancer evaluation as TopoII inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2022.106038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106038"}}